WO2010053340A2 - Composition de blanchiment de la peau - Google Patents
Composition de blanchiment de la peau Download PDFInfo
- Publication number
- WO2010053340A2 WO2010053340A2 PCT/KR2009/006597 KR2009006597W WO2010053340A2 WO 2010053340 A2 WO2010053340 A2 WO 2010053340A2 KR 2009006597 W KR2009006597 W KR 2009006597W WO 2010053340 A2 WO2010053340 A2 WO 2010053340A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- skin
- composition
- final concentration
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 230000002087 whitening effect Effects 0.000 claims abstract description 20
- QRMPRVXWPCLVNI-YYFQZIEXSA-N Curcumol Chemical compound C1C(=C)[C@@H]2CC[C@H](C)[C@@]22C[C@@H](C(C)C)[C@]1(O)O2 QRMPRVXWPCLVNI-YYFQZIEXSA-N 0.000 claims abstract description 19
- VLGATXOTCNBWIT-UHFFFAOYSA-N rubimaillin Chemical compound O1C(C)(C)C=CC2=C1C1=CC=CC=C1C(O)=C2C(=O)OC VLGATXOTCNBWIT-UHFFFAOYSA-N 0.000 claims abstract description 19
- AKPYYGWMASCNAF-UHFFFAOYSA-N methyl 6-hydroxy-2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5-carboxylate Chemical compound O1C(C)(C)CCC2=C1C1=CC=CC=C1C(O)=C2C(=O)OC AKPYYGWMASCNAF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 claims abstract description 11
- CUCUKLJLRRAKFN-UHFFFAOYSA-N 7-Hydroxy-(S)-usnate Chemical compound CC12C(=O)C(C(=O)C)C(=O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O CUCUKLJLRRAKFN-UHFFFAOYSA-N 0.000 claims abstract description 10
- NYSZJNUIVUBQMM-BQYQJAHWSA-N Cardamonin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 NYSZJNUIVUBQMM-BQYQJAHWSA-N 0.000 claims abstract description 10
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 claims abstract description 10
- GMNAPBAUIVITMI-ABNIRSKTSA-N cyclovirobuxine d Chemical compound CC(C)([C@@H](NC)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)NC)[C@H](O)C[C@@]3(C)[C@@H]1CC2 GMNAPBAUIVITMI-ABNIRSKTSA-N 0.000 claims abstract description 10
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 claims abstract description 10
- SDHTXBWLVGWJFT-XKCURVIJSA-N oridonin Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12[C@@H](O)CCC(C)(C)[C@H]1[C@H](O)[C@@]3(O)OC2 SDHTXBWLVGWJFT-XKCURVIJSA-N 0.000 claims abstract description 10
- MBRLOUHOWLUMFF-UHFFFAOYSA-N osthole Chemical compound C1=CC(=O)OC2=C(CC=C(C)C)C(OC)=CC=C21 MBRLOUHOWLUMFF-UHFFFAOYSA-N 0.000 claims abstract description 10
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 claims abstract description 10
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 claims abstract description 9
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 claims abstract description 9
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 claims abstract description 9
- AXGWYABSYNCIMX-UHFFFAOYSA-N Cycloprotobuxin D Natural products C1CC(NC)C(C)(C)C2C31CC13CCC3(C)C(C(C)NC)CCC3(C)C1CC2 AXGWYABSYNCIMX-UHFFFAOYSA-N 0.000 claims abstract description 9
- GMNAPBAUIVITMI-UHFFFAOYSA-N Cyclovirobuxin D Natural products C1CC(NC)C(C)(C)C2C31CC13CCC3(C)C(C(C)NC)C(O)CC3(C)C1CC2 GMNAPBAUIVITMI-UHFFFAOYSA-N 0.000 claims abstract description 9
- HPUXDMUGCAWDFW-UHFFFAOYSA-N Osthole Natural products COc1ccc2CCC(=O)Oc2c1C=CC(=O)C HPUXDMUGCAWDFW-UHFFFAOYSA-N 0.000 claims abstract description 9
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- NYSZJNUIVUBQMM-UHFFFAOYSA-N alpinetin chalcone Natural products COC1=CC(O)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 NYSZJNUIVUBQMM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000009642 cyclovirobuxine D Substances 0.000 claims abstract description 9
- 229940093496 esculin Drugs 0.000 claims abstract description 9
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 claims abstract description 9
- CAQAFLRZJHXSIS-UHFFFAOYSA-N oridonin Natural products CC1(C)C=CC(O)C23COC(O)(C(O)C12)C45C(O)C(CCC34)C(=C)C5=O CAQAFLRZJHXSIS-UHFFFAOYSA-N 0.000 claims abstract description 9
- YBZZAVZIVCBPDJ-UHFFFAOYSA-N schizandrin B Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)(O)CC2=CC2=C1OCO2 YBZZAVZIVCBPDJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940004858 usnic acid Drugs 0.000 claims abstract description 9
- ICTZCAHDGHPRQR-UHFFFAOYSA-N usnic acid Natural products OC1=C(C)C(O)=C(C(C)=O)C2=C1C1(C)C(O)=C(C(=O)C)C(=O)C=C1O2 ICTZCAHDGHPRQR-UHFFFAOYSA-N 0.000 claims abstract description 9
- WEYVVCKOOFYHRW-UHFFFAOYSA-N usninic acid Natural products CC12C(=O)C(C(=O)C)=C(O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O WEYVVCKOOFYHRW-UHFFFAOYSA-N 0.000 claims abstract description 9
- PNTWXEIQXBRCPS-NHCUHLMSSA-N Anomalin Natural products C1=CC(=O)OC2=C3[C@@H](OC(=O)C(C)=CC)[C@@H](OC(=O)C(C)=CC)C(C)(C)OC3=CC=C21 PNTWXEIQXBRCPS-NHCUHLMSSA-N 0.000 claims abstract description 7
- PNTWXEIQXBRCPS-UHFFFAOYSA-N Calipteryxin Natural products C1=CC(=O)OC2=C3C(OC(=O)C(C)=CC)C(OC(=O)C(C)=CC)C(C)(C)OC3=CC=C21 PNTWXEIQXBRCPS-UHFFFAOYSA-N 0.000 claims abstract description 7
- PNTWXEIQXBRCPS-IOWUNYDSSA-N [(9r,10r)-8,8-dimethyl-9-[(z)-2-methylbut-2-enoyl]oxy-2-oxo-9,10-dihydropyrano[2,3-f]chromen-10-yl] (z)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C3[C@@H](OC(=O)C(\C)=C/C)[C@@H](OC(=O)C(\C)=C/C)C(C)(C)OC3=CC=C21 PNTWXEIQXBRCPS-IOWUNYDSSA-N 0.000 claims abstract description 7
- -1 foundation Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000007854 depigmenting agent Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 16
- 230000008099 melanin synthesis Effects 0.000 abstract description 12
- 206010014970 Ephelides Diseases 0.000 abstract description 7
- 208000003351 Melanosis Diseases 0.000 abstract description 7
- 239000002537 cosmetic Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000049 pigment Substances 0.000 abstract description 2
- 206010064127 Solar lentigo Diseases 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
- XYLOFRFPOPXJOQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(piperazine-1-carbonyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(Cn1cc(c(n1)C(=O)N1CCNCC1)-c1cnc(NC2Cc3ccccc3C2)nc1)N1CCc2n[nH]nc2C1 XYLOFRFPOPXJOQ-UHFFFAOYSA-N 0.000 description 1
- XYPHRTDTBOZCJF-UHFFFAOYSA-N Anomaline Natural products CCC12CCC3N(C(=O)C)c4c(O)c(OC)ccc4C35CCN(CCC1O)C25 XYPHRTDTBOZCJF-UHFFFAOYSA-N 0.000 description 1
- 241000521299 Deinocerites cancer Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 208000031066 hyperpigmentation of the skin Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- 230000024181 negative regulation of developmental pigmentation Effects 0.000 description 1
- 229940021584 osthol Drugs 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100001068 severe skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
Definitions
- the present invention relates to a cosmetic for skin whitening, and more particularly, cyclovirobuxine D, osthole, anomaline , Esculin, cardamonin, usnic acid, ordonin, oridonin, schizandrin B, curcumol, mollugin, wogo
- the present invention relates to a nin (wogonin), a dihydromollugin compound, and a composition for skin whitening containing the same, and more particularly, to an external skin composition having an excellent whitening effect.
- Melanogenesis is a defense mechanism against melanocyte melanocytes (melanocytes) that stimulate the production of melanin, which increases melanogenesis, which is transferred to keratinocytes and accumulated in the skin epidermis.
- melanin protects the skin
- hyperpigmentation of the skin causes blemishes, freckles, darkening of the skin after skin inflammation, and senile pigment spots. It may also result.
- the melanin production process is made by tyrosinase, an amino acid called tyrosinase, which is transformed into dopa and dopaquinone, followed by a non-enzymatic oxidation reaction. It is known that spots, blotch, etc. are produced.
- thiol-based compounds such as glutathione and cysteine not only have a characteristic unpleasant odor, but also have problems with transdermal absorption, and glycosides and derivatives thereof have high polarity, making it difficult to use as a cosmetic ingredient.
- the present invention has no side effects on the skin, and excellent in inhibiting melanin production to provide a composition for skin whitening excellent in inhibiting skin pigmentation.
- the present invention provides a melanin production inhibitor selected from the group consisting of compounds represented by the following formulas 1 to 12 excellent in melanin inhibitory effect and whitening effect.
- the present invention also provides a skin whitening agent selected from the group consisting of the compounds represented by Formulas 1 to 12 and a composition for skin whitening containing any one or more of these as an active ingredient.
- compositions such as cosmetics containing as a component can be used very effectively to improve skin hyperpigmentation, such as blemishes, freckles, aging spots and to realize skin whitening.
- the present invention is cyclovirobuxine D of Formula 1 (Cyvivirobuxine D, C 26 H 46 N 2 O, CAS No. 860-79-7), Osthol (Formula 2, C 15 H 16 O 3 , CAS) No. 484-12-8), anmalin of Formula 3 (C 24 H 26 O 7 , CAS No. 81740-07-0), esculin of Formula 4 (C 15 H 16 O 9 , CAS No. 531-75-9), cardamonin of Formula 5 (C 16 H 14 O 4 , CAS No. 18956-16-6), usnic acid of Formula 6 (C 18 H 16 O 7 , CAS No. 125-46-2), orridinin (C20H28O6, CAS No.
- the present inventors conducted a new whitening agent study on native plants and animals using B16 mouse melanoma cells capable of screening even substances that inhibit melanin synthesis induction.
- the compounds of compounds 1 to 5 have been found to have a very strong melanin production inhibitory effect and a whitening effect to complete the present invention.
- the compounds of Formulas 1 to 12 mentioned above may be easily purchased on the market, or each may be used alone or in combination of two or more kinds thereof, such as skin, lotion, cream, foundation, essence, gel, pack, foam cleansing, soap, etc.
- An effective amount may be added to various compositions such as ointments to exhibit skin lightening effects.
- the amount of the compound added is preferably 0.00001 to 10% by weight based on the total weight of the composition, more preferably 0.001 to 1.0% by weight.
- Table 1 sample Melanin production % Inhibition Control group (no addition) 0.044 ⁇ 0.004 - arbutin (final concentration 300 ⁇ g / ml) 0.028 ⁇ 0.004 36 cyclovirobuxine D (final concentration 5 ⁇ g / ml) 0.019 ⁇ 0.003 57 cyclovirobuxine D (final concentration 20 ⁇ g / ml) 0.012 ⁇ 0.002 73 osthole (final concentration 5 ⁇ g / ml) 0.038 ⁇ 0.001 14 osthole (final concentration 20 ⁇ g / ml) 0.028 ⁇ 0.003 36 anomalin (final concentration 5 ⁇ g / ml) 0.025 ⁇ 0.002 43 anomalin (final concentration 20 ⁇ g / ml) 0.018 ⁇ 0.002 59 esculin (final concentration 5 ⁇ g / ml) 0.036 ⁇ 0.002 18 esculin (final concentration 20 ⁇ g / m
- the compounds of Formulas 1 to 12 showed excellent melanin production inhibitory activity even at low concentrations against melanoma cells of cultured rats, compared with arbutin, a whitening substance known in the art, and cytotoxicity Did not appear. This indicates that the present invention can be very useful for improving blemishes and freckles and skin whitening.
- the external application ointment of Preparation Examples 1 to 12 showed a whitening effect on at least 12 of 20 subjects, and showed no side effects in the skin and was safe and improved freckles and freckles. It can be seen that the skin whitening agent has an excellent effect on.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
La présente invention concerne un produit cosmétique de blanchiment de la peau contenant un composé présentant une activité inhibant la production de mélanine. La composition de blanchiment de la peau décrite dans l'invention présente la caractéristique de contenir au moins un composant actif sélectionné dans le groupe comprenant la cyclovirobuxine D, l'osthole, l'anomaline, l'esculine, la cardamonine, l'acide usnique, l'oridonine, la schizandrine B, le curcumol, la mollugine, la wogonine, la dihydromollugine et des mélanges de ceux-ci. Les composés de la présente invention inhibent la production de mélanine et sont particulièrement efficaces pour gêner le dépôt pigmentaire. Ainsi, une composition telle qu'un produit cosmétique contenant un ou plusieurs de ces composés en tant que composant actif peut être utilisée de manière extrêmement efficace pour le blanchiment de la peau, par exemple, pour estomper les tâches de vieillesse et les tâches de rousseur.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080110968A KR101462692B1 (ko) | 2008-11-10 | 2008-11-10 | 피부미백용조성물 |
| KR10-2008-0110968 | 2008-11-10 | ||
| KR1020080120364A KR20100061978A (ko) | 2008-12-01 | 2008-12-01 | 피부미백용조성물 |
| KR10-2008-0120364 | 2008-12-01 | ||
| KR10-2009-0083426 | 2009-09-04 | ||
| KR1020090083426A KR20110025387A (ko) | 2009-09-04 | 2009-09-04 | 피부미백용조성물 |
| KR10-2009-0108077 | 2009-11-10 | ||
| KR1020090108077A KR20110051476A (ko) | 2009-11-10 | 2009-11-10 | 피부미백용조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2010053340A2 true WO2010053340A2 (fr) | 2010-05-14 |
| WO2010053340A3 WO2010053340A3 (fr) | 2010-07-08 |
Family
ID=42153426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2009/006597 WO2010053340A2 (fr) | 2008-11-10 | 2009-11-10 | Composition de blanchiment de la peau |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2010053340A2 (fr) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101244138B1 (ko) | 2011-04-29 | 2013-03-14 | 주식회사 엘지생활건강 | 상피세포 성장인자 생성 촉진용 조성물 |
| US20140107081A1 (en) * | 2011-03-31 | 2014-04-17 | Evocutis Plc | Salicylic acid topical formulation |
| KR101502545B1 (ko) * | 2013-06-19 | 2015-03-13 | 주식회사 엘지생활건강 | 아노말린을 포함하는 피부 볼륨증가 및 주름개선용 화장료 또는 약학 조성물 |
| CN104770362A (zh) * | 2015-03-12 | 2015-07-15 | 西北农林科技大学 | 五味子乙素用于制备猪精液保存用稀释液的应用 |
| KR101560460B1 (ko) | 2013-12-04 | 2015-10-15 | 영남대학교 산학협력단 | 퓨로몰루긴 또는 이의 유도체를 유효성분으로 함유하는 조성물 |
| WO2015167239A1 (fr) * | 2014-04-30 | 2015-11-05 | (주)아모레퍼시픽 | Composition contenant de l'extrait d'impératoire |
| KR101569772B1 (ko) * | 2014-01-08 | 2015-11-17 | 주식회사 엘지생활건강 | 우고닌 또는 이의 약학적으로 허용 가능한 염을 포함하는 다크서클 개선용 화장료 조성물 |
| KR101578461B1 (ko) | 2014-05-12 | 2015-12-18 | 한국콜마주식회사 | 멜라닌 생성억제능의 쿠마린계 화합물로 이루어진 피부 미백제, 그를 함유하는 피부 미백용 조성물 및 상기 쿠마린계 화합물의 분리방법 |
| KR20160001949A (ko) * | 2014-06-30 | 2016-01-07 | (주)아모레퍼시픽 | 산형화 추출물을 포함하는 미백용 조성물 |
| KR101873884B1 (ko) * | 2011-09-01 | 2018-07-04 | (주)아모레퍼시픽 | 에스쿨린 유도체를 포함하는 피부 미백용 조성물 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186653B (zh) * | 2018-03-28 | 2019-10-18 | 苏州大学 | 环维黄杨星d抗登革病毒的应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005084613A1 (fr) * | 2004-03-04 | 2005-09-15 | Veritas Ltd. | Preparation dermique a usage externe |
| US20050271608A1 (en) * | 2004-06-05 | 2005-12-08 | Gupta Shyam K | Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives |
| US20070128302A1 (en) * | 2003-11-07 | 2007-06-07 | Cognis France S.A. | Composition containing an extract of the fruit of schisandra chinensis and process for producing same |
| KR100760875B1 (ko) * | 2006-06-21 | 2007-10-04 | 부경대학교 산학협력단 | 멜라닌 생성 억제 피부미백용 화장품 조성물 |
| US20080254130A1 (en) * | 2003-08-29 | 2008-10-16 | Bioderm Research | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction |
-
2009
- 2009-11-10 WO PCT/KR2009/006597 patent/WO2010053340A2/fr active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080254130A1 (en) * | 2003-08-29 | 2008-10-16 | Bioderm Research | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction |
| US20070128302A1 (en) * | 2003-11-07 | 2007-06-07 | Cognis France S.A. | Composition containing an extract of the fruit of schisandra chinensis and process for producing same |
| WO2005084613A1 (fr) * | 2004-03-04 | 2005-09-15 | Veritas Ltd. | Preparation dermique a usage externe |
| US20050271608A1 (en) * | 2004-06-05 | 2005-12-08 | Gupta Shyam K | Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives |
| KR100760875B1 (ko) * | 2006-06-21 | 2007-10-04 | 부경대학교 산학협력단 | 멜라닌 생성 억제 피부미백용 화장품 조성물 |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140107081A1 (en) * | 2011-03-31 | 2014-04-17 | Evocutis Plc | Salicylic acid topical formulation |
| KR101244138B1 (ko) | 2011-04-29 | 2013-03-14 | 주식회사 엘지생활건강 | 상피세포 성장인자 생성 촉진용 조성물 |
| KR101873884B1 (ko) * | 2011-09-01 | 2018-07-04 | (주)아모레퍼시픽 | 에스쿨린 유도체를 포함하는 피부 미백용 조성물 |
| KR101502545B1 (ko) * | 2013-06-19 | 2015-03-13 | 주식회사 엘지생활건강 | 아노말린을 포함하는 피부 볼륨증가 및 주름개선용 화장료 또는 약학 조성물 |
| KR101560460B1 (ko) | 2013-12-04 | 2015-10-15 | 영남대학교 산학협력단 | 퓨로몰루긴 또는 이의 유도체를 유효성분으로 함유하는 조성물 |
| KR101569772B1 (ko) * | 2014-01-08 | 2015-11-17 | 주식회사 엘지생활건강 | 우고닌 또는 이의 약학적으로 허용 가능한 염을 포함하는 다크서클 개선용 화장료 조성물 |
| WO2015167239A1 (fr) * | 2014-04-30 | 2015-11-05 | (주)아모레퍼시픽 | Composition contenant de l'extrait d'impératoire |
| KR101578461B1 (ko) | 2014-05-12 | 2015-12-18 | 한국콜마주식회사 | 멜라닌 생성억제능의 쿠마린계 화합물로 이루어진 피부 미백제, 그를 함유하는 피부 미백용 조성물 및 상기 쿠마린계 화합물의 분리방법 |
| WO2016003117A1 (fr) * | 2014-06-30 | 2016-01-07 | (주)아모레퍼시픽 | Composition de blanchiment comprenant un extrait d'ombelle |
| KR20160001949A (ko) * | 2014-06-30 | 2016-01-07 | (주)아모레퍼시픽 | 산형화 추출물을 포함하는 미백용 조성물 |
| CN106470693A (zh) * | 2014-06-30 | 2017-03-01 | 株式会社爱茉莉太平洋 | 含大星芹提取物的用于美白肌肤的组合物 |
| TWI685355B (zh) * | 2014-06-30 | 2020-02-21 | 南韓商愛茉莉太平洋股份有限公司 | 以大星芹（Peucedanum Ostruthium）萃取物製備組成物作為美白肌膚、減少黑色素及抑制色素沉著的用途 |
| KR102224312B1 (ko) | 2014-06-30 | 2021-03-09 | (주)아모레퍼시픽 | 산형화 추출물을 포함하는 미백용 조성물 |
| CN104770362A (zh) * | 2015-03-12 | 2015-07-15 | 西北农林科技大学 | 五味子乙素用于制备猪精液保存用稀释液的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010053340A3 (fr) | 2010-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010053340A2 (fr) | Composition de blanchiment de la peau | |
| KR101390061B1 (ko) | 파라-쿠마르산 또는 파라-히드록시신남산 유도체, 및화장용 또는 피부과용 조성물에서의 그의 용도 | |
| KR100855457B1 (ko) | 악틴, 악티게닌 또는 그의 혼합물을 유효성분으로 함유하는피부미백용 화장료 조성물 | |
| KR100825450B1 (ko) | 연교추출물을 함유하는 피부 주름개선용 화장료 조성물 | |
| KR100760875B1 (ko) | 멜라닌 생성 억제 피부미백용 화장품 조성물 | |
| JP2749218B2 (ja) | 美白用化粧料組成物 | |
| KR101919616B1 (ko) | 피부미백용조성물 | |
| KR20140033815A (ko) | 퀴닉산 유도체 및 그의 용도 | |
| KR100538866B1 (ko) | 알로에신 유도체의 합성방법 | |
| KR100454736B1 (ko) | 베라트라민을 함유하는 피부미백용 조성물 | |
| KR20100061978A (ko) | 피부미백용조성물 | |
| KR101462692B1 (ko) | 피부미백용조성물 | |
| KR20160028930A (ko) | 피부미백용조성물 | |
| KR100757130B1 (ko) | 멜라닌 생성 억제 활성을 갖는 베라진 및 에피-베라진을함유하는 피부미백용 화장료 | |
| KR100466379B1 (ko) | 피부미백용 조성물 | |
| KR20130089559A (ko) | 항노화 조성물 | |
| KR100602684B1 (ko) | 망초 추출물을 유효성분으로 함유하는 미백용 화장료조성물 | |
| KR101317433B1 (ko) | 지구자, 길경, 밀싹 및 세이지 추출물을 함유하는 미백 화장용 조성물 | |
| KR102160306B1 (ko) | 피부미백제 | |
| KR101786606B1 (ko) | 테트란드린을 함유하는 화장료 조성물 | |
| KR20100016815A (ko) | 돌나물 추출물 및 알부틴을 함유하는 미백 화장료 조성물 | |
| KR20110051476A (ko) | 피부미백용조성물 | |
| KR101832415B1 (ko) | 레티노이드 유도체를 유효성분으로 함유하는 피부 미백용 화장료 조성물 | |
| KR20010088120A (ko) | 식물 추출물을 함유하는 미백 화장료 조성물 | |
| KR20090105492A (ko) | 아사이베리 추출물을 유효 성분으로 함유하는 미백 화장료조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09825023 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09825023 Country of ref document: EP Kind code of ref document: A2 |